127 related articles for article (PubMed ID: 37019285)
21. An effective AKT inhibitor-PARP inhibitor combination therapy for recurrent ovarian cancer.
Xu J; Gao Y; Luan X; Li K; Wang J; Dai Y; Kang M; Lu C; Zhang M; Lu CX; Kang Y; Xu C
Cancer Chemother Pharmacol; 2022 May; 89(5):683-695. PubMed ID: 35419627
[TBL] [Abstract][Full Text] [Related]
22. Focused Ultrasound Blood-Brain Barrier Opening Arrests the Growth and Formation of Cerebral Cavernous Malformations.
Fisher DG; Sharifi KA; Shah IM; Gorick CM; Breza VR; Debski AC; Hoch MR; Cruz T; Samuels JD; Sheehan JP; Schlesinger D; Moore D; Lukens JR; Miller GW; Tvrdik P; Price RJ
bioRxiv; 2024 Feb; ():. PubMed ID: 38352349
[TBL] [Abstract][Full Text] [Related]
23. Towards Standardisation of a Diffuse Midline Glioma Patient-Derived Xenograft Mouse Model Based on Suspension Matrices for Preclinical Research.
't Hart E; Bianco J; Besse HC; Chin Joe Kie LA; Cornet L; Eikelenboom KL; van den Broek TJM; Derieppe M; Su Y; Hoving EW; Ries MG; van Vuurden DG
Biomedicines; 2023 Feb; 11(2):. PubMed ID: 36831063
[TBL] [Abstract][Full Text] [Related]
24. Focused Ultrasound-Enhanced Liquid Biopsy: A Promising Diagnostic Tool for Brain Tumor Patients.
Bakker A; Ixkes AE; Venugopal H; Ries MG; Lak NSM; de Vos FYFL; van Vuurden DG; Snijders TJ
Cancers (Basel); 2024 Apr; 16(8):. PubMed ID: 38672658
[TBL] [Abstract][Full Text] [Related]
25. Overcoming translational barriers in H3K27-altered diffuse midline glioma: Increasing the drug-tumor residence time.
Power EA; Rechberger JS; Zhang L; Oh JH; Anderson JB; Nesvick CL; Ge J; Hinchcliffe EH; Elmquist WF; Daniels DJ
Neurooncol Adv; 2023; 5(1):vdad033. PubMed ID: 37128506
[TBL] [Abstract][Full Text] [Related]
26. Focused Ultrasound Combined with Microbubbles in Central Nervous System Applications.
Chen KT; Wei KC; Liu HL
Pharmaceutics; 2021 Jul; 13(7):. PubMed ID: 34371774
[TBL] [Abstract][Full Text] [Related]
27. Defining tumor-associated vascular heterogeneity in pediatric high-grade and diffuse midline gliomas.
Wei X; Meel MH; Breur M; Bugiani M; Hulleman E; Phoenix TN
Acta Neuropathol Commun; 2021 Aug; 9(1):142. PubMed ID: 34425907
[TBL] [Abstract][Full Text] [Related]
28. Epidemiology, Diagnostic Strategies, and Therapeutic Advances in Diffuse Midline Glioma.
Miguel Llordes G; Medina Pérez VM; Curto Simón B; Castells-Yus I; Vázquez Sufuentes S; Schuhmacher AJ
J Clin Med; 2023 Aug; 12(16):. PubMed ID: 37629304
[No Abstract] [Full Text] [Related]
29. Therapeutic avenues for targeting treatment challenges of diffuse midline gliomas.
Noon A; Galban S
Neoplasia; 2023 Jun; 40():100899. PubMed ID: 37030112
[TBL] [Abstract][Full Text] [Related]
30. Venetoclax Cooperates with Ionizing Radiation to Attenuate Diffuse Midline Glioma Tumor Growth.
Madhavan K; Balakrishnan I; Lakshmanachetty S; Pierce A; Sanford B; Fosmire S; Elajaili HB; Walker F; Wang D; Nozik ES; Mitra SS; Dahl NA; Vibhakar R; Venkataraman S
Clin Cancer Res; 2022 Jun; 28(11):2409-2424. PubMed ID: 35344040
[TBL] [Abstract][Full Text] [Related]
31. The distribution, clearance, and brainstem toxicity of panobinostat administered by convection-enhanced delivery.
Singleton WGB; Bienemann AS; Woolley M; Johnson D; Lewis O; Wyatt MJ; Damment SJP; Boulter LJ; Killick-Cole CL; Asby DJ; Gill SS
J Neurosurg Pediatr; 2018 Sep; 22(3):288-296. PubMed ID: 29856296
[TBL] [Abstract][Full Text] [Related]
32. BET bromodomain inhibition potentiates radiosensitivity in models of H3K27-altered diffuse midline glioma.
Watanabe J; Clutter MR; Gullette MJ; Sasaki T; Uchida E; Kaur S; Mo Y; Abe K; Ishi Y; Takata N; Natsumeda M; Gadd S; Zhang Z; Becher OJ; Hashizume R
J Clin Invest; 2024 May; ():. PubMed ID: 38771655
[TBL] [Abstract][Full Text] [Related]
33. An EZH2 blocker sensitizes histone mutated diffuse midline glioma to cholesterol metabolism inhibitors through an off-target effect.
Rahal F; Capdevielle C; Rousseau B; Izotte J; Dupuy JW; Cappellen D; Chotard G; Ménard M; Charpentier J; Jecko V; Caumont C; Gimbert E; Grosset CF; Hagedorn M
Neurooncol Adv; 2022; 4(1):vdac018. PubMed ID: 35300150
[TBL] [Abstract][Full Text] [Related]
34. Imipridones affect tumor bioenergetics and promote cell lineage differentiation in diffuse midline gliomas.
Przystal JM; Cianciolo Cosentino C; Yadavilli S; Zhang J; Laternser S; Bonner ER; Prasad R; Dawood AA; Lobeto N; Chin Chong W; Biery MC; Myers C; Olson JM; Panditharatna E; Kritzer B; Mourabit S; Vitanza NA; Filbin MG; de Iuliis GN; Dun MD; Koschmann C; Cain JE; Grotzer MA; Waszak SM; Mueller S; Nazarian J
Neuro Oncol; 2022 Sep; 24(9):1438-1451. PubMed ID: 35157764
[TBL] [Abstract][Full Text] [Related]
35. The intrinsic and microenvironmental features of diffuse midline glioma: Implications for the development of effective immunotherapeutic treatment strategies.
Persson ML; Douglas AM; Alvaro F; Faridi P; Larsen MR; Alonso MM; Vitanza NA; Dun MD
Neuro Oncol; 2022 Sep; 24(9):1408-1422. PubMed ID: 35481923
[TBL] [Abstract][Full Text] [Related]
36. Anti-tumour efficacy on glioma models of PHA-848125, a multi-kinase inhibitor able to cross the blood-brain barrier.
Albanese C; Alzani R; Amboldi N; Degrassi A; Festuccia C; Fiorentini F; Gravina G; Mercurio C; Pastori W; Brasca M; Pesenti E; Galvani A; Ciomei M
Br J Pharmacol; 2013 May; 169(1):156-66. PubMed ID: 23347136
[TBL] [Abstract][Full Text] [Related]
37. Enhancement in blood-tumor barrier permeability and delivery of liposomal doxorubicin using focused ultrasound and microbubbles: evaluation during tumor progression in a rat glioma model.
Aryal M; Park J; Vykhodtseva N; Zhang YZ; McDannold N
Phys Med Biol; 2015 Mar; 60(6):2511-27. PubMed ID: 25746014
[TBL] [Abstract][Full Text] [Related]
38. [Effect and Mechanism of Radiosensitization of Poly (ADP-Ribose) Polymerase Inhibitor n Lewis Cells and Xenografts].
Wang W; Duan B; Zeng L
Zhongguo Fei Ai Za Zhi; 2016 Jan; 19(1):16-23. PubMed ID: 26805733
[TBL] [Abstract][Full Text] [Related]
39. Optimal therapeutic targeting by HDAC inhibition in biopsy-derived treatment-naïve diffuse midline glioma models.
Vitanza NA; Biery MC; Myers C; Ferguson E; Zheng Y; Girard EJ; Przystal JM; Park G; Noll A; Pakiam F; Winter CA; Morris SM; Sarthy J; Cole BL; Leary SES; Crane C; Lieberman NAP; Mueller S; Nazarian J; Gottardo R; Brusniak MY; Mhyre AJ; Olson JM
Neuro Oncol; 2021 Mar; 23(3):376-386. PubMed ID: 33130903
[TBL] [Abstract][Full Text] [Related]
40. Focused ultrasound-induced blood-brain barrier opening to enhance temozolomide delivery for glioblastoma treatment: a preclinical study.
Wei KC; Chu PC; Wang HY; Huang CY; Chen PY; Tsai HC; Lu YJ; Lee PY; Tseng IC; Feng LY; Hsu PW; Yen TC; Liu HL
PLoS One; 2013; 8(3):e58995. PubMed ID: 23527068
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
